Heron Therapeutics (0J4V) Ratios
3 Followers
Heron Therapeutics Ratios
GB:0J4V's free cash flow for Q2 2026 was $-2.35M. For the 2026 fiscal year, GB:0J4V's free cash flow was decreased by $-138.00K and operating cash flow was $-2.21M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.48 | 2.29 | 2.37 | 2.49 | 3.58 |
| Quick Ratio | 1.51 | 1.70 | 1.84 | 1.83 | 2.90 |
| Cash Ratio | 0.30 | 0.28 | 0.36 | 0.19 | 1.27 |
| Solvency Ratio | -0.07 | -0.04 | -0.42 | -0.75 | -0.95 |
| Operating Cash Flow Ratio | -0.29 | -0.25 | -0.74 | -1.78 | -2.86 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -3.48M | $ -57.78M | $ -67.70M | $ -31.94M | $ 26.29M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.55 | 0.76 | 0.81 | 0.63 | 0.52 |
| Debt-to-Equity Ratio | 9.81 | -5.28 | -5.29 | 11.60 | 2.06 |
| Debt-to-Capital Ratio | 0.91 | 1.23 | 1.23 | 0.92 | 0.67 |
| Long-Term Debt-to-Capital Ratio | 0.91 | 1.24 | 1.24 | 0.92 | 0.66 |
| Financial Leverage Ratio | 17.85 | -6.93 | -6.55 | 18.49 | 3.94 |
| Debt Service Coverage Ratio | 0.00 | -0.84 | -26.83 | -71.41 | -89.32 |
| Interest Coverage Ratio | 0.00 | -1.91 | -28.60 | -70.60 | -90.39 |
| Debt to Market Cap | 0.65 | 0.75 | 0.74 | 0.55 | 0.17 |
| Interest Debt Per Share | 0.84 | 1.21 | 1.33 | 1.47 | 1.64 |
| Net Debt to EBITDA | -6.26 | -30.06 | -1.45 | -0.80 | -0.32 |
| Profitability Margins | |||||
| Gross Profit Margin | 73.31% | 73.21% | 48.75% | 49.04% | 46.70% |
| EBIT Margin | -13.04% | -5.23% | -83.98% | -166.76% | -252.79% |
| EBITDA Margin | -11.54% | -3.50% | -81.70% | -164.07% | -249.29% |
| Operating Profit Margin | -1.64% | -7.99% | -87.07% | -162.21% | -252.27% |
| Pretax Profit Margin | -13.04% | -9.41% | -87.02% | -169.05% | -255.58% |
| Net Profit Margin | -13.04% | -9.41% | -87.02% | -169.05% | -255.58% |
| Continuous Operations Profit Margin | -13.04% | -9.41% | -87.02% | -169.05% | -255.58% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 795.71% | 117.80% | 99.95% | 104.22% | 101.31% |
| Return on Assets (ROA) | -7.89% | -5.82% | -49.69% | -72.53% | -72.19% |
| Return on Equity (ROE) | -140.90% | 40.36% | 325.43% | -1341.17% | -284.50% |
| Return on Capital Employed (ROCE) | -1.59% | -8.14% | -77.45% | -103.60% | -92.83% |
| Return on Invested Capital (ROIC) | -1.59% | -7.97% | -75.82% | -101.97% | -91.89% |
| Return on Tangible Assets | -7.89% | -5.82% | -49.69% | -72.53% | -72.19% |
| Earnings Yield | -9.32% | -5.82% | -47.08% | -66.80% | -24.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.73 | 1.83 | 2.11 | 2.07 | 2.43 |
| Payables Turnover | 4.60 | 3.30 | 17.14 | 15.29 | 11.88 |
| Inventory Turnover | 0.45 | 0.73 | 1.55 | 1.01 | 0.95 |
| Fixed Asset Turnover | 12.49 | 8.17 | 4.96 | 3.61 | 2.57 |
| Asset Turnover | 0.61 | 0.62 | 0.57 | 0.43 | 0.28 |
| Working Capital Turnover Ratio | 1.19 | 1.27 | 1.09 | 0.70 | 0.44 |
| Cash Conversion Cycle | 950.43 | 591.02 | 387.56 | 515.57 | 503.07 |
| Days of Sales Outstanding | 211.09 | 199.55 | 172.77 | 176.44 | 150.06 |
| Days of Inventory Outstanding | 818.74 | 502.05 | 236.08 | 363.00 | 383.73 |
| Days of Payables Outstanding | 79.40 | 110.58 | 21.30 | 23.87 | 30.72 |
| Operating Cycle | 1029.83 | 701.60 | 408.86 | 539.44 | 533.79 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.17 | -0.15 | -0.43 | -1.35 | -2.07 |
| Free Cash Flow Per Share | -0.17 | -0.16 | -0.44 | -1.36 | -2.10 |
| Dividend Paid and CapEx Coverage Ratio | -87.04 | -13.21 | -38.05 | -80.50 | -67.29 |
| Capital Expenditure Coverage Ratio | -87.04 | -13.21 | -38.05 | -80.50 | -67.29 |
| Operating Cash Flow Coverage Ratio | -0.20 | -0.13 | -0.33 | -0.93 | -1.27 |
| Operating Cash Flow to Sales Ratio | -0.18 | -0.16 | -0.46 | -1.36 | -2.36 |
| Free Cash Flow Yield | -12.88% | -10.39% | -25.69% | -54.58% | -22.96% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.83 | -17.17 | -2.12 | -1.50 | -4.07 |
| Price-to-Sales (P/S) Ratio | 1.40 | 1.62 | 1.85 | 2.53 | 10.41 |
| Price-to-Book (P/B) Ratio | 15.12 | -6.93 | -6.91 | 20.08 | 11.59 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.77 | -9.62 | -3.89 | -1.83 | -4.36 |
| Price-to-Operating Cash Flow Ratio | -7.85 | -10.35 | -3.99 | -1.85 | -4.42 |
| Price-to-Earnings Growth (PEG) Ratio | -0.31 | 0.19 | 0.04 | 0.06 | 0.39 |
| Enterprise Value Multiple | -18.38 | -76.19 | -3.72 | -2.35 | -4.50 |
| Enterprise Value | 328.71M | 385.21M | 385.78M | 414.60M | 967.99M |
| EV to EBITDA | -18.38 | -76.19 | -3.72 | -2.35 | -4.50 |
| EV to Sales | 2.12 | 2.67 | 3.04 | 3.85 | 11.21 |
| EV to Free Cash Flow | -11.78 | -15.89 | -6.39 | -2.79 | -4.69 |
| EV to Operating Cash Flow | -11.91 | -17.10 | -6.56 | -2.82 | -4.76 |
| Tangible Book Value Per Share | 0.09 | -0.22 | -0.25 | 0.12 | 0.79 |
| Shareholders’ Equity Per Share | 0.09 | -0.22 | -0.25 | 0.12 | 0.79 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.93 | 0.95 | 0.92 | 0.99 | 0.88 |
| Net Income Per Share | -0.12 | -0.09 | -0.80 | -1.67 | -2.24 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.80 | 1.04 | 1.01 | 1.01 |
| Research & Development to Revenue | 0.08 | 0.12 | 0.31 | 0.77 | 1.52 |
| SG&A to Revenue | 0.67 | 0.70 | 0.46 | 0.58 | 0.47 |
| Stock-Based Compensation to Revenue | 0.07 | 0.09 | 0.26 | 0.40 | 0.54 |
| Income Quality | 1.37 | 1.66 | 0.53 | 0.81 | 0.92 |
Currency in USD
